Industry News
Biotechnology Industry News
Ocelot Bio gets a cool $36M series A and a new CEO to boot
Ocelot Bio gets a cool $36M series A and a new CEO to boot ssorensen Tue, 03/22/2022 - 11:29
ORIC walks away from lead cancer resistance program after lackluster phase 1b data
ORIC walks away from lead cancer resistance program after lackluster phase 1b data aarmstrong Tue, 03/22/2022 - 09:58
Aligos hacks off 2nd hep B med since January after ‘unexpected’ reaction in 4 patients
Aligos hacks off 2nd hep B med since January after 'unexpected' reaction in 4 patients mbayer Tue, 03/22/2022 - 09:57
Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases
Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseases aarmstrong Tue, 03/22/2022 - 09:04
After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a strategic portfolio review in his wake
After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a strategic portfolio review in his wake ntaylor Tue, 03/22/2022 - 07:40
Ex-Biogen R&D chief Al Sandrock lands CEO job at Voyager, taking over the Big Pharma darling in early days of its turnaround strategy
Ex-Biogen R&D chief Al Sandrock lands CEO job at Voyager, taking over the Big Pharma darling in early days of its turnaround strategy ntaylor Tue, 03/22/2022 - 05:43
Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field
Bayer-backed Affini-T snags $175M to enter increasingly crowded KRAS-cancer field mbayer Mon, 03/21/2022 - 16:44
Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to RSV vaccine candidate in $225M deal
Chasing Big Pharma trio, Bavarian Nordic sells Chinese rights to RSV vaccine candidate in $225M deal ntaylor Mon, 03/21/2022 - 09:08
Immunogen’s phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing
Immunogen's phase 3 ADC survival data spook investors, sending stock down ahead of FDA filing ntaylor Mon, 03/21/2022 - 07:40
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones ‘ringing off the hook’
Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones 'ringing off the hook' mbayer Fri, 03/18/2022 - 14:06
Summit says path forward for failed C. difficile drug is likely through partnerships
Summit says path forward for failed C. difficile drug is likely through partnerships mbayer Fri, 03/18/2022 - 10:42
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts
Protalix eyes Fabry drug resubmission thanks to multiple phase 3 readouts klahucik Fri, 03/18/2022 - 09:24
Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trial
Onconova takes early steps on long road back, filing to raise dose cap in solid tumor trial ntaylor Fri, 03/18/2022 - 08:48
After megaround, Apexigen inks modest SPAC deal to advance melanoma prospect toward approval
After megaround, Apexigen inks modest SPAC deal to advance melanoma prospect toward approval ntaylor Fri, 03/18/2022 - 07:28
Zosano’s headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission
Zosano's headaches continue: Biotech lays off 31% after FDA rejects migraine drug resubmission klahucik Thu, 03/17/2022 - 16:22
Chutes & Ladders—Former Translate CMO Ann Barbier is moving to Camp4 Therapeutics in the same role
Chutes & Ladders—Former Translate CMO Ann Barbier is moving to Camp4 Therapeutics in the same role mbayer Thu, 03/17/2022 - 15:51
‘Stay alive’: Wave of layoffs crashes into biotech startup inferno
'Stay alive': Wave of layoffs crashes into biotech startup inferno klahucik Thu, 03/17/2022 - 12:35
NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron shakes up study
NIH squashes Synairgen’s COVID therapy from ACTIV-2 trial after omicron shakes up study mbayer Thu, 03/17/2022 - 10:42
Athenex cuts jobs, narrows focus to cell therapies in continued fallout from 2021 FDA rejection
Athenex cuts jobs, narrows focus to cell therapies in continued fallout from 2021 FDA rejection klahucik Thu, 03/17/2022 - 10:09
Sensorion spins hearing loss flop into exploratory win in attempt to revive lead program
Sensorion spins hearing loss flop into exploratory win in attempt to revive lead program aarmstrong Thu, 03/17/2022 - 09:55